Engineered Nanoplatform with Dual Anti-Inflammatory and Microbiota-Modulating Actions for Targeted Therapy in Chronic...

Area of Science:

• Biomedical Engineering
• Gastroenterology
• Nanotechnology

Background:

• Inflammatory bowel disease (IBD) is a chronic gastrointestinal disorder marked by oxidative stress, poor antioxidant defenses, and gut dysbiosis.
• Current IBD therapies have limitations in efficacy and cause systemic side effects.

Purpose of the Study:

• To develop a multifunctional nanoplatform for targeted IBD treatment.
• To investigate the therapeutic potential of a nanoplatform combining antioxidant reinforcement and microbiota regulation.

Main Methods:

• Encapsulation of superoxide dismutase (SOD) within Cu-doped ZIF-zc, coated with bacterial ghosts (BG/SOD@ZIF-zc).
• Evaluation of the nanoplatform's stability, enzymatic activity, ROS scavenging, and microbiota modulation.
• Assessment of therapeutic effects in zebrafish models of intestinal inflammation.

Main Results:

• The BG/SOD@ZIF-zc nanoplatform maintained SOD activity in the gastrointestinal environment.
• The system effectively scavenged reactive oxygen species and optimized gut microbiota composition.
• In zebrafish, BG/SOD@ZIF-zc reduced intestinal inflammation, enhanced antioxidant activity, decreased lipid peroxidation, and improved anxiety-like behavior.

Conclusions:

• The developed nanoplatform offers a dual-action therapeutic strategy for IBD.
• This approach integrates antioxidant reinforcement with microbiota modulation for improved IBD management.
• BG/SOD@ZIF-zc represents a promising therapeutic candidate for inflammatory bowel disease.